Key Highlights

  • Cue Biopharma (NASDAQ:CUE) reported a third-quarter net loss of USD 50.0 million, or USD 4.74 a share, against USD 7.4 million, or USD 2.22, a year earlier, for the quarter ended September 30, 2026.
  • General and administrative expense rose to USD 29.8 million from USD 4.9 million, with USD 24.7 million of the USD 24.9 million increase coming from higher stock-based compensation.
  • Research and development expense climbed to USD 17.0 million from USD 4.8 million, while collaboration Revenue fell to USD 0.1 million from USD 2.1 million.
  • Cash and cash equivalents were USD 57.9 million at September 30, 2026, and the company says this funds operations for at least the next twelve months, though it needs substantial additional capital.

Stock Awards Push Administrative Costs to USD 29.8 Million

Cue Biopharma (NASDAQ:CUE) reported a net loss of USD 50.0 million for the quarter ended September 30, 2026, compared with USD 7.4 million a year earlier, or USD 4.74 a share against USD 2.22. The company is a clinical-stage biopharmaceutical Business whose lead asset, CUE-221, is an anti-IgE antibody for allergic disease, alongside CUE-401, an autoimmune candidate designed to build regulatory T cell tolerance. The largest driver was general and administrative expense, which reached USD 29.8 million from USD 4.9 million. The USD 24.9 million increase came from employee compensation tied to a new management team in 2026, including a USD 24.7 million rise in stock-based compensation, mainly restricted stock units granted in July 2026.

Research Spending Triples as Collaboration Revenue Slows

Research and development expense rose to USD 17.0 million from USD 4.8 million. Compensation accounted for USD 9.7 million of the USD 12.2 million increase, of which USD 9.3 million was stock-based, and clinical trial costs added USD 2.2 million. Collaboration revenue fell to USD 0.1 million from USD 2.1 million as activity under the Boehringer Ingelheim agreement progressed as planned. The operating loss was USD 47.1 million against USD 7.6 million, and a USD 3.4 million charge for changes in the Fair Value of financial instruments pushed other items further into loss. Over nine months, the net loss was USD 208.3 million against USD 28.2 million, including a USD 90.0 million loss on liability-classified warrants and USD 35.9 million of research license fees.

Cash of USD 57.9 Million Meets a Heavy Cash Burn

Operating activities used USD 50.0 million of cash in the nine months against USD 20.6 million a year earlier, while financing added USD 81.0 million. A July private Placement sold 1,418,071 shares at USD 33.21, plus pre-funded warrants for 87,500 shares, for net proceeds of about USD 49.8 million. The Ascendant license signed on April 30, 2026 carried a USD 15.0 million upfront payment and up to USD 676.5 million of potential milestones, and one-time license-related outflows were about USD 28 million. Dosing in a Phase 1 trial of CUE-401 began in October 2026. The company had 8,359,523 shares outstanding on November 13, 2026, after a 1-for-30 reverse split in April.

Where Things Stand

Cue Biopharma swung to a USD 50.0 million quarterly loss because stock-based pay for a new management team and higher research spending arrived in the same quarter that collaboration revenue shrank. Much of the increase is non-cash Equity compensation, and management says the USD 57.9 million cash balance covers at least twelve months, so the filing does not flag Going Concern doubt. Even so, cash use is rising and the company states it needs substantial additional capital. Next markers are the CUE-401 Phase 1 progress, further Ascendant milestone triggers and any new equity raise.